Q2 2025 Xtant Medical Holdings Inc Earnings Call Transcript
Key Points
- Xtant Medical Holdings Inc (XTNT) reported a strong financial performance with total revenue for Q2 2025 at $35.4 million, marking an 18% increase compared to the same period in 2024.
- The company achieved a positive adjusted EBITDA, net income, and cash flow from operations for the second quarter, reflecting strong top-line performance and effective expense management.
- Xtant Medical Holdings Inc (XTNT) launched new biologic products, including OsteoFactor Pro and Trivium, enhancing their product portfolio and contributing to revenue growth.
- The company successfully became the first fully vertically integrated biologics company to manufacture all products in-house, improving gross margins and ensuring high product quality.
- Xtant Medical Holdings Inc (XTNT) raised its full-year 2025 revenue guidance to a range of $131 million to $135 million, representing growth of approximately 11% to 15% over 2024 revenue.
- The hardware product family experienced a 20% year-over-year decline, negatively impacting overall revenue growth.
- There is uncertainty regarding the continuation of strong licensing revenue in the fourth quarter of 2025, which could affect future financial performance.
- Gross margins are expected to decline by 4 to 5 points in the second half of 2025 due to reduced royalty revenue and hardware growth.
- The sale of noncore assets, while beneficial for focus and debt reduction, means the company will lose approximately $23.5 million in annual revenue run rate.
- The anticipated closing of the sale of noncore assets is not solely at the company's discretion, introducing uncertainty in financial planning.
Good morning, everyone, and welcome to the Xtant Medical second quarter 2025 financial results.(Operator Instructions) Please note this conference being recorded.
I will now turn the conference over to your host, Kevin Gardner of LifeSci Advisors. The floor is yours.
Thank you, operator, and welcome to Xtant Medical's second quarter 2025 and financial results call. Joining me today are Sean Browne, President and Chief Executive Officer; and Scott Neils, Chief Financial Officer. Today's call is being webcast and will be posted on the company's website for playback.
During the course of this call, management may make certain forward-looking statements regarding future events and the company's expected future performance. These forward-looking statements reflect Xtant's current perspective on existing trends and information and can be identified by such words as expect, plan, will, may, anticipate, believe, should, intends and other words with similar meaning. Such forward-looking statements are not
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
